Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: April 17, 2025
Event Date: April 15, 2025
Context: The Company entered into a Material Definitive Agreement to acquire assets from The Sleep Center of Nevada (SCN), a Nevada professional corporation. This transaction represents a strategic expansion into sleep testing, diagnostics, and treatment centers.
Key Financial Metrics and Transaction Terms
This filing details a specific acquisition agreement rather than periodic financial results. Key financial terms of the Asset Purchase Agreement include:
- Total Consideration Structure:
- Cash Payment: $6.0 million (subject to adjustments prior to closing).
- Restricted Common Stock (Upfront): $1.5 million based on the 30-day VWAP preceding the closing date.
- Contingent "Earn-out" Stock: $1.5 million in restricted Common Stock based on the 30-day VWAP following the achievement of an agreed-upon financial milestone by the acquired centers.
- Liabilities Assumed: Specific trade accounts payable and liabilities related to assigned SCN contracts.
- Financing Requirement: The Company states it must finance the $6.0 million cash portion as it lacks sufficient current cash on hand. Funding is intended to be secured via a senior debt facility and potential equity financing.
- Employment Costs: An employment agreement with Dr. Prabhu Rachakonda includes an annual salary of $400,000 plus customary benefits.
Note: The filing does not provide current revenue, profit, cash flow, margins, or total debt figures for Vivos Therapeutics, Inc. as of the reporting date.
Material Changes and Transaction Status
Acquisition Status: The transaction is pending and subject to several closing conditions, including:
- Accuracy of representations and warranties.
- Receipt of third-party consents.
- Completion of satisfactory due diligence and receipt of a quality of earnings report.
- Absence of material adverse change regarding SCN.
Timeline: Closing is expected to occur later in the current quarter (Q2 2025) or in the third quarter of 2025. It is not subject to stockholder approval.
Operational Impact: Upon closing, the acquired assets and liabilities will be held in a subsidiary. Ancillary agreements include transition services and practice administration agreements to maintain compliance with corporate practice of medicine doctrines.
Guidance, Risks, and Contingencies
Management Commentary: Management anticipates the acquisition will expand the Company's marketing and distribution model. However, no definitive agreement has been reached regarding the debt facility required to fund the cash portion of the purchase price.
Key Risks and Contingencies:
- Financing Risk: The Company may be unable to finance the cash portion of the acquisition on favorable terms, or at all.
- Closing Risk: The transaction is subject to conditions that may not be satisfied, potentially preventing the closing.
- Operational Risk: Risks associated with regulatory scrutiny in the sleep apnea sector and the possibility that patients may not achieve desired results.
- Market Risk: Risks related to maintaining Nasdaq listing and securing additional financing in the future.
Forward-Looking Statements: The filing contains forward-looking statements regarding the timing of the closing and future revenue impacts, which are subject to significant uncertainties.
Investor Verification Checklist
- Verify the status of the senior debt facility and equity financing required to fund the $6.0 million cash payment.
- Monitor the satisfaction of closing conditions, specifically the quality of earnings report and third-party consents.
- Review the specific financial milestones required to trigger the $1.5 million contingent "earn-out" stock payment.
- Assess the Company's current cash position and liquidity runway in light of the pending acquisition costs.
- Examine the full text of the Asset Purchase Agreement (Exhibit 2.1) for detailed representations, warranties, and indemnification provisions.